Reaction profile

The FDA adverse-event record for depigmentation of nasal plane

37 FDA reports name depigmentation of nasal plane, a lower-volume reaction in the CVM extract (VeDDRA 2177). Plate stamps and neighbourhood peers follow.

#1891 of 2,481
by report volume (all reactions)
37
reports citing this reaction
5.4%
death-coded share
Dog
most-affected species

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Depigmentation of nasal plane has 37 reports now versus 37 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Depigmentation of nasal plane changes

FDA AER · VeDDRA plate

Code 2177 VOL-TRACE

VOL-TRACE · DEATH-PAR · LOWER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

  • VOL-TRACE 37 reports
  • DEATH-PAR 5.4%
  • LOWER-Q #1891/2481
  • PHOTO-FINISH Blistering of mouth
  • SPECIES-DOG Dog · 36
  • DRUG-LEAD Toceranib Phospha… · 7
  • DESK-WIDE 20 breeds
  • BOOK-FULL 8/8 fields

Nearest volume peer: Blistering of mouth (±0 reports)

Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.

Lower-volume neighbourhood around Depigmentation of nasal plane

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

Vomiting · highest174348Blistering of mouth · near37CARBON DIOXIDE HIGH,… · near37Cartilage degeneration · near37Cleft palate · near37Depigmentation of nas… · thi…37Urinary tract neoplas… · low…10
FDA AER report volume · neighbourhood around Depigmentation of nasal plane

Depigmentation of nasal plane: low death-coded share in the FDA AER plate

Signature read: 2 death-coded reports is a thin tail count for Depigmentation of nasal plane in the CVM extract. Report volume is lower-third scale: 37 named reports in the openFDA extract. Death-coded share is lower-third: 2 of 37 reports (5.4% of named reports). Nearest volume peer: Blistering of mouth (±0 reports). Lead species Dog (36). Lead co-reported drug Toceranib Phosphate (7).

Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Toceranib Phosphate appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 36
Horse 1

Breeds Most Affected

Retriever - Labrador 7
Shepherd Dog - German 5
Crossbred Canine/dog 4
Boxer (German Boxer) 2
Retriever - Golden 2
Bulldog - French 2
Spaniel - King Charles Cavalier 2
Akita 1
Collie - Border 1
Terrier - Yorkshire 1

Associated Drugs

Toceranib Phosphate 7
Oclacitinib Maleate 7
Afoxolaner 5
Ivermectin + Pyrantel As Pamoate Salt 5
Afoxolaner 68 Mg Chewable Tablets 4
Maropitant Citrate 2
Prednisone 2
Carprofen 1
Cefazolin 1
Broad Spectrum Antibiotics 1
Fresh Frozen Plasma 1
Vitamin K 1
Butorphenol 1
Pentobarbital Sodium And Phenytoin Sodium 1
Clindamycin Oral Solution 1
Propofol 1
Midazolam 1
Hydromorphone 1
Intravenous Fluids 1
Bordetella Vaccine 1

What to do with this reaction

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Depigmentation of nasal plane (#1891 of 2,481 by report volume); death-coded 5.4%. PlainBreed reaction plate · death-coded report count stamp 2 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →